{"schema_version":"secwatch.filing_event.v1","accession":"0001835268-25-000026","form_type":"8-K","ticker":"CNTB","cik":"0001835268","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.032515+00:00","generated_at":"2026-05-21T17:35:41.278724+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Connect Biopharma initiates Phase 2 Seabreeze STAT study of rademikibart for acute asthma exacerbations","bullets":["Phase 2 Seabreeze STAT Asthma study (NCT06940141) initiated after FDA agreement on final protocol.","Evaluates rademikibart as adjunct to standard of care in ~160 adults/adolescents with type 2 inflammation asthma.","Primary endpoint: treatment failure rate over 28 days; secondary include exacerbations and lung function.","Topline data expected in first half of 2026.","Imminently on track to initiate a similarly-designed Phase 2 study in COPD."],"urls":{"canonical":"https://secwatch.observer/filing/0001835268-25-000026","json":"https://secwatch.observer/filing/0001835268-25-000026.json","markdown":"https://secwatch.observer/filing/0001835268-25-000026.md","text":"https://secwatch.observer/filing/0001835268-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835268/000183526825000026/0001835268-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835268/000183526825000026/cntb-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T17:35:41.278724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}